Press Releases May 1, 2026 08:00 AM

Abercrombie & Fitch Co. to Report First Quarter 2026 Results on May 27, 2026

Abercrombie & Fitch Co. schedules Q1 2026 earnings report and conference call for May 27, 2026.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
ANF

Abercrombie & Fitch Co. announced that it will release its first quarter 2026 financial results on May 27, 2026, followed by a conference call and webcast accessible to all interested parties. The company operates globally with a focus on digitally-led omnichannel retail of apparel and accessories targeting kids through millennials.

Abercrombie & Fitch Co. to Report First Quarter 2026 Results on May 27, 2026
ANF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Abercrombie & Fitch Co. will report Q1 2026 earnings on May 27, 2026, with a conference call and webcast for investors.
  • The company operates approximately 830 stores worldwide under Abercrombie and Hollister brands along with robust e-commerce platforms.
  • Focus on digitally-led omnichannel retail targeting younger demographics including kids and millennials across multiple geographies.

NEW ALBANY, Ohio, May 01, 2026 (GLOBE NEWSWIRE) -- Abercrombie & Fitch Co. (NYSE: ANF) will host its quarterly earnings conference call for all interested parties on Wednesday, May 27, 2026, at 8:30 a.m. ET. A press release detailing the company’s first quarter results is expected to be issued shortly after 7:30 a.m. ET.   In addition, a presentation of the first quarter results will be available on the company’s website at approximately 7:30 a.m. ET.

Conference Call:To access the conference call by phone, participants will need to register to obtain a dial-in phone number and an access code. Register for the call using this link.  Webcast:To listen to a live webcast of the call, please visit corporate.abercrombie.com/investors/news-and-events/events/ and click the link to the webcast.  Replay:A replay of the webcast will be available at corporate.abercrombie.com/investors shortly after the call ends and will be archived for one year.

Further information is available at corporate.abercrombie.com. Important information may be disseminated initially or exclusively via the website: investors should consult the site to access this information.

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co. (NYSE: ANF) is a global, digitally led omnichannel specialty retailer of apparel and accessories catering to kids through millennials with assortments curated for their specific lifestyle needs.

The company operates a family of brands, including Abercrombie brands and Hollister brands, each sharing a commitment to offer products of enduring quality and exceptional comfort that support global customers on their journey to being and becoming who they are. Abercrombie & Fitch Co. operates approximately 830 stores under these brands across North America, Europe, Asia and the Middle East, as well as the e-commerce sites abercrombie.com, abercrombiekids.com, and hollisterco.com.

Investor Contact: Media Contact:Mo Gupta Kate WagnerAbercrombie & Fitch Co. Abercrombie & Fitch Co.(614) 283-6751 (614) 283-6192Investor_Relations@anfcorp.com Public_Relations@anfcorp.com



Risks

  • Performance depends on consumer discretionary spending trends impacting retail apparel sector.
  • Global operations expose the company to international market risks and supply chain disruptions.
  • Continued digital transformation and competition in e-commerce presents challenges to maintaining growth and profitability.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026